SeikagakuSKUNF +0.91%72 EBITDA Margin % is 23.50% as of Mar. 2026, which is 74% above its 10-year median of 13.51. GuruFocus rates SKUNF with a GF Score™ of 72/100 and a GF Value™ of $17.00 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Seikagaku ranks better than 55.81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Seikagaku's EBITDA for the
three
months ended in Mar. 2026 was $14.4 Mil. Seikagaku's Revenue for the
three
months ended in Mar. 2026 was $61.2 Mil. Therefore, Seikagaku's EBITDA margin for the quarter that ended in Mar. 2026 was 23.50%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Seikagaku EBITDA Margin % Related Terms
Seikagaku EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Seikagaku's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKUNF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Seikagaku's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seikagaku EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Seikagaku's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Seikagaku's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seikagaku (SKUNF) has a EBITDA Margin % of 23.50% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Seikagaku and its competitors. This is 74% above median its historical median of 13.51. According to the industry distribution chart, Seikagaku ranks #361 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 44.2%.
Is Seikagaku's EBITDA Margin % too high?
Seikagaku's current EBITDA Margin % of 23.50% is 74% above median its 10-year median of 13.51. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Seikagaku's value of 23.50% is 215.9% above this industry median. Based on the distribution chart, Seikagaku ranks #361 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Seikagaku has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Seikagaku's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Seikagaku ranks #361 out of 817 companies for EBITDA Margin %. This puts Seikagaku in the upper half of its industry. The industry median EBITDA Margin % is 7.44. Seikagaku's value of 23.50% is 215.9% above this benchmark. While the company's 10-year median is 13.51 vs. the industry median of 7.44, Seikagaku has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seikagaku's current EBITDA Margin % of 23.50% is 215.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Seikagaku and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seikagaku's current EBITDA Margin % is 23.50%, which is 74% above median its own 10-year median of 13.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seikagaku stock overvalued right now?
Based on GuruFocus' analysis, Seikagaku (SKUNF) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.00, compared to a current price of $4.44 — trading 73.9% below its estimated fair value. The current EBITDA Margin % is 23.50%, which is 74% above median its 10-year median of 13.51 and 215.9% above the Medical Devices & Instruments industry median of 7.44. Seikagaku's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Seikagaku (SKUNF), the current EBITDA Margin % is 23.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seikagaku (SKUNF) Overvalued in 2026?
Based on GuruFocus' analysis, Seikagaku stock appears to be undervalued.
The current stock price of $4.44 is trading 73.9% below its estimated GF Value™ of $17.00.
GuruFocus considers Seikagaku to be Significantly Undervalued.
Key valuation signals for SKUNF:
EBITDA Margin %: 23.50% (74% above median its 10-year median of 13.51)
GF Value™: $17.00 vs. price of $4.44 (73.9% below fair value)
Industry Position: 215.9% above the Medical Devices & Instruments median (#361 of 817)
No single metric tells the full story. See the SKUNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.
72GF Score
Get the complete analysis for SKUNF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SKUNF has been successfully added to your 
